文献速递膀胱癌与上尿路尿路上皮癌

女性与肌层浸润性膀胱癌治疗模式及结局的关联

Associations Between Female Sex and Treatment Patterns and Outcomes for Muscle-invasive Bladder Cancer.
PubMed 文献 · Urology · 2020-07-14

该研究基于SEER-Medicare数据库纳入2004至2014年6809例非转移性肌层浸润性膀胱癌患者,分析性别与治疗选择及生存的关系。结果显示女性更可能接受根治性膀胱切除术(OR 1.39,95%CI 1.20-1.61),但膀胱癌特异性生存更差(HR 1.18,95%CI 1.05-1.32),总生存无差异,且其他原因死亡率更低。

要点

  • 女性非转移性肌层浸润性膀胱癌患者接受根治性膀胱切除术的几率显著高于男性。
  • 女性膀胱癌特异性生存较男性更差,但总生存无显著差异。
  • pT4a期患者中男女总生存和膀胱癌特异性生存无差异。

核心结论

  • 女性性别预测更积极的根治性膀胱切除术治疗,但膀胱癌特异性生存反而更差。
  • 女性膀胱癌特异性生存劣势削弱了其总生存优势。

研究设计与样本

  • 回顾性队列研究,使用SEER-Medicare数据集。
  • 纳入2004至2014年初诊为非转移性肌层浸润性膀胱癌的6809例患者。

主要发现

  • 2528例(37%)接受根治性膀胱切除术,4281例(63%)接受替代性保膀胱干预。
  • 女性接受膀胱切除术的比值比(OR)为1.39(95%CI 1.20-1.61)。
  • 女性较男性诊断时年龄更大且合并症更少(P <.001)。
  • 女性膀胱癌特异性生存的风险比(HR)为1.18(95%CI 1.05-1.32)。
  • 总生存的女性HR为0.93(95%CI 0.86-1.01),其他原因死亡HR为0.78(95%CI 0.70-0.86)。

临床怎么用

  • 临床应关注女性肌层浸润性膀胱癌患者膀胱癌特异性生存更差的现象。
  • 性别差异可能影响治疗决策与预后评估,需个体化考量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association of female sex with the selected treatment for patients with nonmetastatic muscle-invasive bladder cancer. Sex is a known independent predictor of death from bladder cancer. A potential explanation for this survival disparity is difference in treatment pattern and stage presentation among males and females. MATERIALS AND METHODS: Using the surveillance, epidemiology, and end results-medicare data set, we identified 6809 patients initially diagnosed with nonmetastatic muscle-invasive bladder cancer between 2004 and 2014. We fit multivariable logistic regression and Cox models to assess the relationship of sex with treatment modality and survival adjusting for differences in patient characteristics. RESULTS: Of the 6809 patients with nonmetastatic muscle invasive bladder cancer, 2528 (37%) received a radical cystectomy while 4281 (63%) received an alternative bladder sparing intervention. Women were significantly more likely to receive a cystectomy (odds ratios [OR] 1.39; 95% confidence intervals [CI] 1.20-1.61), present at an older age with less comorbidities compared to men (P <.001). Women were also found to have worse bladder cancer-specific survival (CSS) than men (hazard ratio [HR] 1.18; 95% CI 1.05-1.32), no difference in overall survival (OS) (female HR 0.93; 0.86-1.01) and lower mortality from other causes (HR 0.78; 95% CI 0.70-0.86). There were no differences in OS and CSS by sex in patients with stage pT4a. CONCLUSION: Female sex predicted more aggressive treatment with radical cystectomy yet worse cancer-specific survival than males. This sex disparity in CSS reduced the known OS advantage observed in women.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Grajales V, Bandari J, Hale NE, et al. Associations Between Female Sex and Treatment Patterns and Outcomes for Muscle-invasive Bladder Cancer. Urology. 2020. PMID: 32673679. doi:10.1016/j.urology.2020.06.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。